Revenue beat, profit crushed; margins under siege
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met FY27 growth target (18.4% H1 vs 18–20% annual); margin guidance hedged then explicitly lowered to 16–17% near-term.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
DOMS delivered 17.6% YoY revenue growth in-line with FY27 18–20% guidance, but PAT collapsed –37% YoY and EBITDA margin compressed to 12.4% vs. 16–17% target. Management is passing only 4–5% of 15% raw material inflation (3–4 month lag), has doubled debt to ~₹200 Cr to fund aggressive capex, and offers no clear timeline for margin recovery. Reynolds acquisition is still in trial production with uncertain payoff. Hold pending evidence of pricing power or RM stabilization.
₹667.8 Cr
Revenue · +17.6% YoY₹38.3 Cr
Reported PAT · −37% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
volume growth 18%-odd, 80% volume-led, 20% realization
YoY revenue +17.6%, but input cost inflation ~15% with only 4-5% pricing pass-through
OVERSTATED
sustained revenue growth with healthy volume expansion
H1 FY27 revenue +18.4% YoY, but PAT -37% QoQ and margin at 5.7% vs historical 6%+
Partially Supported
EBITDA margins at 12.4% both Q2 and H1, moving towards 16-17%
Delivered 12.4%, but target 16-17% admitted as near-term unachievable; RM inflation not yet fully passed
MISS
Reynolds acquisition strategic, expected revenue Q3 FY27 onwards
First building commissioned, trial production started, overhead ~0.5-1% of sales; timeline uncertain ('probably 1 year then 9 months')
OVERSTATED
One-off ₹10.4 Cr loss from flooding, expected insurance recovery
Acknowledged exceptional loss; recovery status unknown, already claimed in P&L
MET
Earnings quality
What changed since the last call
Margin target clarity (reduced)
DowngradePrior call: 'margin guidance limited due to RM volatility, target return to 16–17%.' This call: 16–17% now explicitly acknowledged as near-term unachievable; current 12.4% margin a temporary blip pending RM stabilization or aggressive pricing.
Debt levels (doubled)
DowngradeH1 FY27 debt risen to ~₹200 Cr (vs ~₹100 Cr prior year). Driven by capex (₹200 Cr H1 + ₹100–125 Cr H2 planned) and Reynolds acquisition. Management views as strategic but strain on cash flow evident.
Reynolds revenue accretion timeline (pushed back)
DowngradeAcquisition closed July 2026; assets relocated to new facility. Trial production started but timeline to scale now 'probably 1 year, then 9 months'—much longer than initial optimistic messaging.
PAT trajectory (deteriorated sharply)
DowngradeQ2 PAT ₹38.3 Cr (–37% YoY); H1 PAT ₹83.6 Cr at 6.2% margin. Despite 18.4% H1 revenue growth, profit underperformance severe. NPM compressed from 6%+ to 5.7%.
Pricing power stance (more cautious)
NeutralPrior: 'measured approach to pricing.' Current: 'measured approach' + 'couple of quarters patience' + 'three scenarios' for margin recovery. Tone shifted from confidence to explicit uncertainty.
The Q&A
Analysts (Sneha, Aniruddha, Aradhana, Rina, Jinesh, Rahul Agarwal, Bhavin) pressed hard on margins, inflation lag, Reynolds payoff, and debt. Management held line on growth thesis but admitted 'very difficult to guide' on margin recovery, repeated 'wait couple of quarters' mantra, and deflected on margin timeline to future calls. Q&A score 6/10: transparent on facts but defensive on near-term outlook.
RM inflation & price pass-through — Sneha, Nivama Wealth
AnsweredOverall inflation ~15%, pricing passed ~4–5%. Acknowledged near-term margin pressure but prefer 'patient' approach. Long-term target 16–17% EBITDA once RM stabilizes. Will evaluate 'couple of quarters' before aggressive pricing.
Reynolds acquisition & integration — Anirududdha Joshi, ICICI Securities
PartialFirst building commissioned, trial production started (Brite, 045 pens, click pens). Pricing kept constant (MRP). Revenue contribution Q3 FY27 onwards expected. Integration done by July 1. Distribution overlaps consolidated.
Cost inflation & capex breakdown — Aradhana Jain, 360 ONE Capital
AnsweredOverall inflation ~15% H1. Segmental: nursery, stationery, adhesives pricing. Capex ₹200 Cr H1 mostly 50-acre facility & greenfield plant. Flexible on allocation based on demand.
Guidance drivers & regional performance — Rina Mehta, Trident Capital
PartialDrivers: capacity additions, adhesives, back-to-school. West not underperforming; calibrated to population. Merchant exporter issues from Bangladesh geopolitical impacts.
Reynolds cannibalization & capex phasing — Jinesh Joshi, PL Capital
AnsweredReynolds not replacement; assets were only molds/machines. Original plan was pens (bigger opportunity) but war delayed 6–8 month machinery lead times. Pens prioritized in plan; pencils have opportunity but low current share.
Inflation scenario planning & debt trajectory — Jinesh Joshi (continued)
PartialPrefer patience; three scenarios possible. Debt rise from capex (IPO + debt-funded incremental) + Reynolds + working capital. Views debt as strategic; expects paydown once margins normalize.
RM pricing direction & margin visibility — Rahul Agarwal, Ikigai Asset Management
DodgedRM prices likely at peak but continuing to rise (October > September). 'Very difficult to guide' due to volatility. Margin visibility limited. Will focus operational agility; no specific near-term margin guide.
Reynolds overhead costs & scaling timeline — Bhavin Rupani, Investec
AnsweredReynolds overhead ~0.5–1% of Q2 sales. Just started production. Trade very excited. Timeline: probably 1 year then 9 months to scale. Margins once normalized will be similar to DOMS core.
Post-inflation scenario & growth implications — Bhavin Rupani (continued)
DodgedDeferred to January/February call for clarity on inflation evolution & capacity deployment impact. Growth target 18–20% to 'continue near to midterm for sure.'
Guidance
FY27 consolidated sales growth 18–20%
HighReaffirmed. H1 at 18.4% on track. Q2 alone 17.6% YoY. Broad-based growth across all segments & categories.
EBITDA margin 16–17% long-term target
LowNear-term margin pressure acknowledged. Current 12.4% vs target 16–17%. Recovery timeline hedged: 'couple of quarters patience' pending RM stabilization & pricing actions.
Baby hygiene segment EBITDA 8–10% target
MediumCurrent 8.1% → 6.4% due to higher RM consumption. Expected to recover as pricing and consumption normalize.
FY27 total ₹250–275 Cr capex deployed
HighH1 ₹200 Cr invested (mostly 50-acre greenfield & Reynolds asset purchase). H2 expect ₹100–125 Cr more for buildings 2–4 and machinery.
Risks the call surfaced
Raw material cost inflation
HighRM cost inflation ~15% but only passing 4–5% pricing. 2-month inventory buffer + 3–4 month sales cycle creates margin lag. If inflation persists, margin recovery delayed.
Margin recovery uncertainty
HighManagement targets 16–17% EBITDA margins but delivered 12.4%. Timeline to recovery hedged ('couple of quarters'). If RM inflation persists or pricing doesn't materialize, margin recovery could slip into FY28.
Reynolds acquisition payoff
MediumReynolds acquisition closed July 2026. Trial production started but scaling timeline now stated as 'probably 1 year then 9 months.' Overhead ~0.5–1% of sales. Risk of prolonged slow ramp or margin dilution.
Debt sustainability
HighDebt nearly doubled to ~₹200 Cr (vs ~₹100 Cr prior year) due to capex spend (₹200 Cr H1) and working capital build. Margin compression at 12.4% reduces cash flow. H2 capex ₹100–125 Cr planned. Risk of prolonged leverage if margin recovery delayed.
Export market geopolitical exposure
MediumWest region export sales to Bangladesh via merchant exporters impacted by geopolitical conditions. Sales previously high; now weakened. Affects regional growth profile.
Management
Score 6/10. CFO Rahul Shah articulate and granular on operational detail (segment breakdown, capacity status, RM lag mechanics). Transparent on challenges (margin pressure, debt rise, timing uncertainty). But defensive on forward outlook; repeated 'wait a couple of quarters,' 'very difficult to guide,' and deferred margin clarity to Jan/Feb 2027. On-track on capex (₹200 Cr H1, plan ₹250–275 Cr full year). Revenue growth 18.4% H1 met FY27 18–20% target. But margin guidance miss (12.4% vs 16–17% target) and PAT down 37% YoY show execution constraints. New products launched but scale/timing uncertain.
1 · Q3 FY27 (Oct–Dec 2026)
Reynolds writing instruments production scale-up and sales ramp. Trade anticipation high; timeline uncertain.
2 · H2 FY27 (Oct 2026–Mar 2027)
Second & third buildings at 50-acre site come on-stream; pencil & office supplies capacity to drive growth. Scholastic & back-to-school season momentum.
3 · Q3–Q4 FY27 (by Jan 2027)
Management to provide clarity on margin recovery timeline & inflation persistence. Capital deployment plan for new buildings.
Hold pending evidence of pricing power or RM stabilization.
Informational and educational content only. Not investment advice.